Qianhai Health Holdings Limited (0911.HK)
HKD 0.21
(-8.7%)
HKD 0.21
(-8.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -52.18 Million HKD | 80.07% |
| 2022 | -256.79 Million HKD | -5439.04% |
| 2021 | -4.63 Million HKD | -196.58% |
| 2020 | 4.8 Million HKD | -82.92% |
| 2019 | 28.1 Million HKD | 303.16% |
| 2018 | -13.83 Million HKD | -146.44% |
| 2017 | 29.79 Million HKD | 106.61% |
| 2016 | -450.93 Million HKD | -27.91% |
| 2015 | -352.54 Million HKD | -246.07% |
| 2014 | 241.35 Million HKD | 47.23% |
| 2013 | 163.93 Million HKD | 167.55% |
| 2012 | 61.27 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 17.66 Million HKD | 0.0% |
| 2024 Q1 | 17.66 Million HKD | -71.06% |
| 2023 Q3 | 30.01 Million HKD | 126.75% |
| 2023 Q1 | -56.1 Million HKD | 69.17% |
| 2023 FY | -51.18 Million HKD | 80.07% |
| 2023 Q4 | 61.02 Million HKD | 103.33% |
| 2023 Q2 | -112.21 Million HKD | -100.0% |
| 2022 Q4 | -181.97 Million HKD | -100.0% |
| 2022 Q3 | -90.98 Million HKD | -604.62% |
| 2022 Q1 | 9.01 Million HKD | 97.32% |
| 2022 FY | -256.79 Million HKD | -5439.04% |
| 2022 Q2 | 18.03 Million HKD | 100.0% |
| 2021 Q4 | 4.56 Million HKD | 152.42% |
| 2021 FY | -4.63 Million HKD | -196.58% |
| 2021 Q1 | 688 Thousand HKD | -89.6% |
| 2021 Q2 | -20.62 Million HKD | -3097.67% |
| 2021 Q3 | -8.71 Million HKD | 57.74% |
| 2020 Q1 | 4.84 Million HKD | -61.09% |
| 2020 Q2 | 9.69 Million HKD | 100.0% |
| 2020 Q3 | -3.68 Million HKD | -137.97% |
| 2020 Q4 | 6.61 Million HKD | 279.71% |
| 2020 FY | 4.8 Million HKD | -82.92% |
| 2019 Q4 | 12.46 Million HKD | 91.8% |
| 2019 Q2 | -1.67 Million HKD | -100.24% |
| 2019 Q1 | -836 Thousand HKD | 95.41% |
| 2019 FY | 28.1 Million HKD | 303.16% |
| 2019 Q3 | 6.49 Million HKD | 488.11% |
| 2018 FY | -13.83 Million HKD | -146.44% |
| 2018 Q4 | -18.22 Million HKD | 0.0% |
| 2018 Q3 | -18.22 Million HKD | -282.91% |
| 2018 Q2 | -4.76 Million HKD | 0.0% |
| 2018 Q1 | -4.76 Million HKD | 37.53% |
| 2017 Q1 | -3.88 Million HKD | 97.97% |
| 2017 FY | 29.79 Million HKD | 106.61% |
| 2017 Q2 | -3.88 Million HKD | 0.0% |
| 2017 Q4 | -7.62 Million HKD | 0.0% |
| 2017 Q3 | -7.62 Million HKD | -95.99% |
| 2016 Q4 | -191.8 Million HKD | 0.0% |
| 2016 Q3 | -191.8 Million HKD | -406.41% |
| 2016 Q2 | -37.87 Million HKD | 0.0% |
| 2016 Q1 | -37.87 Million HKD | 90.36% |
| 2016 FY | -450.93 Million HKD | -27.91% |
| 2015 Q2 | 239.25 Million HKD | 0.0% |
| 2015 Q3 | -392.7 Million HKD | -264.14% |
| 2015 FY | -352.54 Million HKD | -246.07% |
| 2015 Q1 | 239.25 Million HKD | 5212.61% |
| 2015 Q4 | -392.7 Million HKD | 0.0% |
| 2014 Q3 | 4.5 Million HKD | -96.39% |
| 2014 Q1 | 124.67 Million HKD | 596.32% |
| 2014 FY | 241.35 Million HKD | 47.23% |
| 2014 Q4 | 4.5 Million HKD | 0.0% |
| 2014 Q2 | 124.67 Million HKD | 0.0% |
| 2013 Q2 | 59.99 Million HKD | 0.0% |
| 2013 Q4 | 17.9 Million HKD | 0.0% |
| 2013 Q3 | 17.9 Million HKD | -70.16% |
| 2013 Q1 | 59.99 Million HKD | 46.4% |
| 2013 FY | 163.93 Million HKD | 167.55% |
| 2012 FY | 61.27 Million HKD | 0.0% |
| 2012 Q4 | 40.98 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 136.489% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 101.959% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | -539.341% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 227.649% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 244.784% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 116.815% |
| Tongfang Kontafarma Holdings Limited | - HKD | Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 20.99% |
| SSY Group Limited | 1.63 Billion HKD | 103.184% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 129.955% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 115.665% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.43% |